Indivior (NASDAQ:INDV) Shares Gap Down - What's Next?

Key Points

• Shares gapped down from $32.83 to an $30.00 open and are trading around $30.64 (down ~6.9%) on volume of ~1.22M, with a 50-day/200-day moving average of $33.93/$30.53 and a market cap of $3.82B.
• Analyst sentiment is largely positive—six Buys and one Hold—with an average price target of $39.33 and recent upside revisions (HC Wainwright to $48, Northland to $50, Weiss upgraded to Buy).
• Indivior recently beat expectations (Q reported EPS $0.82 vs. $0.65 estimate; revenue $358M vs. $305.6M) but shows a negative ROE (−148.76%); insiders have added modestly to positions and institutions own ~60.3% of the stock.

Indivior PLC (NASDAQ:INDV - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $32.83, but opened at $30.00. Indivior shares last traded at $30.6410, with a volume of 1,223,924 shares.

Analyst Upgrades and Downgrades

Several research firms have issued reports on INDV. HC Wainwright lifted their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a "buy" rating in a research report on Monday, January 12th. Northland Securities set a $50.00 price objective on Indivior in a research note on Tuesday, January 20th. Morgan Stanley reaffirmed an "overweight" rating and set a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings raised Indivior from a "hold (c)" rating to a "buy (b-)" rating in a report on Monday, March 2nd. Finally, Zacks Research lowered Indivior from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Indivior has an average rating of "Moderate Buy" and an average price target of $39.33.

Indivior Trading Down 6.9%

The company's 50-day moving average is $33.93 and its 200 day moving average is $30.53. The firm has a market cap of $3.82 billion, a PE ratio of 18.67 and a beta of 0.83.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. The company had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. On average, research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Insider Transactions at Indivior

In other Indivior news, Director Mark Stejbach acquired 775 shares of the firm's stock in a transaction on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,847 shares of the company's stock, valued at $596,215.33. The trade was a 4.82% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith Humphreys bought 775 shares of the stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 5,802 shares in the company, valued at approximately $205,332.78. This represents a 15.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 5,842 shares of company stock worth $203,342.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INDV. Salomon & Ludwin LLC acquired a new stake in shares of Indivior during the 4th quarter valued at $30,000. Harbor Capital Advisors Inc. increased its stake in shares of Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company's stock worth $37,000 after acquiring an additional 781 shares during the last quarter. CWM LLC acquired a new position in shares of Indivior in the third quarter worth $25,000. Quarry LP purchased a new stake in shares of Indivior during the third quarter worth $26,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company's stock worth $39,000 after acquiring an additional 460 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company's stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.